ARTICLE | Clinical News
Teverelix LA: Phase IIa data
February 21, 2005 8:00 AM UTC
Data from a European Phase IIa trial in the first set of 14 patients showed that in 93% of patients Teverelix LA led to a reduction in testosterone levels equivalent to those of castrated men (0.5 ng/...